RedHill Biopharma (RDHL) Net Equity Issued and Repurchased (2013 - 2022)

RedHill Biopharma (RDHL) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $7.6 million in Q4 2022.

• On a quarterly basis, Net Equity Issued and Repurchased fell 61.74% year-over-year to $7.6 million in Q4 2022; TTM through Dec 2022 was $23.8 million, a 69.69% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 6.04% from the prior year.
• Net Equity Issued and Repurchased for Q4 2022 stood at $7.6 million, down from $15.5 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for RDHL reached as high as $57.9 million in Q1 2021 and fell as low as $273000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $14.0 million across 4 years, with a median of $8.8 million in 2020.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 5580.59% in 2022 and fell as far as 98.77% in 2022.
• Year by year, Net Equity Issued and Repurchased stood at $18.3 million in 2018, then plunged by 54.4% to $8.4 million in 2020, then jumped by 136.92% to $19.8 million in 2021, then plunged by 61.74% to $7.6 million in 2022.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $7.6 million in Q4 2022, $15.5 million in Q2 2022, and $713000.0 in Q1 2022.